Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

Mol Cancer Ther (2021) 20 (12): 2352–2361.

https://doi.org/10.1158/1535-7163.MCT-21-0370

Published: 03 December 2021

View article titled, Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

Includes: Supplementary data

Journal Articles

PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus

Gabriel B. Mpilla, Md. Hafiz Uddin, Mohammed N. Al-Hallak, Amro Aboukameel, Yiwei Li, Steve H. Kim, Rafic Beydoun, Gregory Dyson, Erkan Baloglu, William T. Senapedis, Yosef Landesman, Kay-Uwe Wagner, Nerissa T. Viola, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi

Mol Cancer Ther (2021) 20 (10): 1836–1845.

https://doi.org/10.1158/1535-7163.MCT-20-1105

Published: 01 October 2021

View article titled, PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus

Includes: Supplementary data

Journal Articles

Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma

John A. DeSisto, Patrick Flannery, Rakeb Lemma, Amrita Pathak, Shelby Mestnik, Natalie Philips, Natalie J. Bales, Trinayan Kashyap, Erin Moroze, Sujatha Venkataraman, Andrew L. Kung, Bruce D. Carter, Yosef Landesman, Rajeev Vibhakar, Adam L. Green

Mol Cancer Ther (2020) 19 (2): 540–551.

https://doi.org/10.1158/1535-7163.MCT-18-1319

Published: 06 February 2020

View article titled, Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma

Includes: Supplementary data

Journal Articles

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu, Y. Lynn Wang

Mol Cancer Ther (2018) 17 (12): 2564–2574.

https://doi.org/10.1158/1535-7163.MCT-17-0789-ATR

Published: 03 December 2018

View article titled, XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Includes: Supplementary data

Journal Articles

Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

Kateryna Krytska, Kathryn Evans, Tara Pritchard, Matthew Tsang, Raymond Yung, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Erkan Baloglu, Yosef Landesman, Kyle A. Jensen, William Senapedis, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock, John M. Maris

Mol Cancer Ther (2018) 17 (1_Supplement): LB-B14.

https://doi.org/10.1158/1535-7163.TARG-17-LB-B14

Published: 01 January 2018

View article titled, Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

Journal Articles

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

Matthew R. Farren, Rebecca C. Hennessey, Reena Shakya, Omar Elnaggar, Gregory Young, Kari Kendra, Yosef Landesman, Sivan Elloul, Marsha Crochiere, Boris Klebanov, Trinayan Kashyap, Christin E. Burd, Gregory B. Lesinski

Mol Cancer Ther (2017) 16 (3): 417–427.

https://doi.org/10.1158/1535-7163.MCT-16-0498

Published: 02 March 2017

View article titled, The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

Includes: Supplementary data

Journal Articles

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Paul M. Tyler, Mariah M. Servos, Romy C. de Vries, Boris Klebanov, Trinayan Kashyap, Sharon Sacham, Yosef Landesman, Michael Dougan, Stephanie K. Dougan

Mol Cancer Ther (2017) 16 (3): 428–439.

https://doi.org/10.1158/1535-7163.MCT-16-0496

Published: 02 March 2017

View article titled, Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Includes: Supplementary data

Journal Articles

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi

Mol Cancer Ther (2017) 16 (1): 76–87.

https://doi.org/10.1158/1535-7163.MCT-16-0205

Published: 05 January 2017

View article titled, Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Includes: Supplementary data

Journal Articles

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

Sabiha Kazim, Mokenge P. Malafa, Domenico Coppola, Kazim Husain, Sherma Zibadi, Trinayan Kashyap, Marsha Crochiere, Yosef Landesman, Tami Rashal, Daniel M. Sullivan, Amit Mahipal

Mol Cancer Ther (2015) 14 (7): 1570–1581.

https://doi.org/10.1158/1535-7163.MCT-15-0104

Published: 06 July 2015

View article titled, Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

Includes: Supplementary data

Journal Articles

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Yan Cheng, Michael P. Holloway, Kevin Nguyen, Dilara McCauley, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, Rachel A. Altura

Mol Cancer Ther (2014) 13 (3): 675–686.

https://doi.org/10.1158/1535-7163.MCT-13-0416

Published: 09 March 2014

View article titled, XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

William Senapedis, Marsha Crochiere, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Jean-Richard Saint-Martin, Ori Kalid, Sharon Shechter, Diego del Alamo, Mwanasha Hamuza, Gali Golan, Eran Shacham, Sharon Tamir, Dilara McCauley, Erkan Baloglu, Michael Kauffman, Sharon Shacham, Yosef Landesman

Mol Cancer Ther (2013) 12 (11_Supplement): B198.

https://doi.org/10.1158/1535-7163.TARG-13-B198

Published: 01 November 2013

View article titled, Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

Journal Articles

Abstract C49: Using single cell fluorescent cell cycle reporters to study mechanisms of action of selective inhibitors of nuclear export (SINE).

Joshua Marcus, Yosef Landesman, Sharon Shacham, James Orth

Mol Cancer Ther (2013) 12 (11_Supplement): C49.

https://doi.org/10.1158/1535-7163.TARG-13-C49

Published: 01 November 2013

View article titled, Abstract C49: Using single cell fluorescent cell cycle reporters to study mechanisms of action of selective inhibitors of nuclear export (SINE).

Journal Articles

Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

Marsha L. Crochiere, Trinayan Kashyap, Jean-Richard Saint-Martin, Sharon Shechter, Ori Kalid, Eran Shacham, William Senapedis, Boris Klebanov, Sharon Tamir, Diego del Alamo, Mwanasha Hamuza, Gali Golan, Erkan Baloglu, Dilara McCauley, Michael Kauffman, Sharon Shacham, Yosef Landesman

Mol Cancer Ther (2013) 12 (11_Supplement): A188.

https://doi.org/10.1158/1535-7163.TARG-13-A188

Published: 01 November 2013

View article titled, Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

Journal Articles

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack

Mol Cancer Ther (2013) 12 (7): 1171–1179.

https://doi.org/10.1158/1535-7163.MCT-12-1171

Published: 07 July 2013

View article titled, CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Includes: Supplementary data

NARROW

Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus

Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

Abstract C49: Using single cell fluorescent cell cycle reporters to study mechanisms of action of selective inhibitors of nuclear export (SINE).

Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only